Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents

Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park and Byung Soo Kim

Abstract
Background: Although many acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients have been treated with hypomethylating agents (HMAs) as a substitute for intensive chemotherapy in recent years, the incidence of invasive fungal infections (IFIs) and the efficacy of posaconazole as antifungal prophylaxis in these patients are not well known to date.

Methods: We retrospectively analyzed 280 AML and MDS patients treated with HMAs to identify IFI incidence and posaconazole efficacy as antifungal prophylaxis in these patients.

Results: The overall incidence of probable or proven IFIs was 7.9% (22/280 patients): 11.5% in the no-use group (17/148 patients) and 3.8% in the posaconazole group (5/132 patients). Most IFIs occurred during the early cycles of the HMAs (median: 3 cycles; range: 1–8 cycles), especially in patients who had neutropenia or did not respond to HMAs. Posaconazole significantly lowered IFI incidence compared with that in the no-use group in univariate and multivariate analyses. Moreover, patients who had reduced liver function at HMA initiation, were treated with decitabine therapy, and did not respond to HMA chemotherapy were independently associated with a higher IFI risk. In subgroup analysis, posaconazole appeared to be more beneficial for patients with good Eastern Cooperative Oncology Group performance score or liver function at HMA initiation.

Conclusion: Thus, in AML and MDS patients receiving HMAs, IFI risk may be high during the early cycles, especially when the underlying disease is not controlled. Posaconazole could represent antifungal prophylaxis in these patients; further studies are needed for its appropriate indications.

Keywords: antifungal prophylaxis, hypomethylating agent, invasive fungal infection, posaconazole

Received: 30 June 2020; revised manuscript accepted: 23 September 2020.
supportive care or even conventional intensive chemotherapy. Although the incidence of prolonged severe neutropenia is not as high as that of intensive chemotherapy, HMAs may cause cytopenia, including neutropenia, and increase transfusion demand. In addition, considering that AML and MDS themselves are risk factors for febrile neutropenia, the use of antimicrobial prophylaxis during HMA treatment needs to be discussed. However, unfortunately, there is a lack of information on the risk of infection, including IFI, and the use of antifungal prophylaxis in patients treated with HMAs for AML and MDS.

Posaconazole is an oral azole with a wide spectrum, including species of Candida, Aspergillus, Fusarium, and Zygomycetes. Cornely et al. reported that posaconazole prevented IFIs and improved survival more effectively than fluconazole or itraconazole in patients receiving chemotherapy for AML or MDS. Since then, several guidelines have recommended the use of posaconazole as antifungal prophylaxis in these patients. However, this study was conducted mainly in AML and MDS patients who received intensive chemotherapy; therefore, the effect of posaconazole on patients receiving HMAs is unclear. Thus, the present study was conducted prospectively to identify the incidence of IFIs in AML and MDS patients treated with HMAs and confirm the efficacy of posaconazole as antifungal prophylaxis in these patients.

Methods

Study design and patients

This was a non-interventional comparative cohort study, in which we retrospectively analyzed the data of patients who were consecutively enrolled in the AML and MDS Registry from January 2006 to April 2020. Three affiliated tertiary hospitals (Anam, Guro, and Ansan hospitals) located in the metropolitan area participated in the registry. The study was approved by the institutional review board, and all data were fully anonymized (IRB No. 2020AN0211, 2020GR0237, and 2020AS0137).

Patients who met the following inclusion criteria were selected: (1) patients with a diagnosis of AML or MDS according to the World Health Organization classification; (2) patients first exposed to HMAs (azacytidine or decitabine) as first-line chemotherapy; and (3) patients who received at least one full cycle of either drug. Azacytidine and decitabine were administered at the recommended dose of 75 mg/m² subcutaneously or intravenously (IV) daily for 7 days every 4 weeks and 20 mg/m² IV daily for 5 days every 4 weeks, respectively. The use of posaconazole was determined at the discretion of the participating physicians according to the patients' insurance coverage and the risk of IFI as judged by a physician, and posaconazole was administered at the recommended dose of 300 mg once a day (maintenance dose) after 300 mg twice a day (loading dose) from chemotherapy day 1 until neutropenia recovery.

Clinical endpoints

The primary endpoints were the incidence of IFIs in the AML and MDS patients treated with the HMAs and the efficacy of posaconazole as antifungal prophylaxis. We counted probable or proven IFIs that occurred during treatment with the HMAs (from the time of HMA initiation to before second-line chemotherapy or allogeneic hematopoietic stem cell transplantation), and each IFI was defined according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria. In brief, a proven IFI was defined as a case that satisfied any one of the following criteria: (1) identification of fungal elements (molds or yeasts) through microscopic analysis with sterile material; (2) the detection of fungal elements (molds or yeasts) through culture with sterile material or blood; and (3) identification of fungal elements (applies only to yeasts) through serological analysis of cerebrospinal fluid. A probable IFI was defined as a case that satisfied all three of the following conditions: the presence of a host factor, a clinical criterion, and a mycological criterion. Details are presented in Supplemental Material Table 1 online.

The secondary endpoint was the characteristics of patients who would benefit from posaconazole use. The following data were collected: age, diagnosis of AML or MDS, cytogenetics–molecular risk stratification of AML classified according to the 2017 European LeukemiaNet criteria, prognostic risk groups of MDS divided according to the revised international prognostic scoring
system,\textsuperscript{26} Eastern Cooperative Oncology Group performance score (ECOG PS),\textsuperscript{27} absolute neutrophil count (ANC), Child–Pugh score (CPS),\textsuperscript{28} chronic kidney disease (CKD) stage\textsuperscript{29} based on estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation at the initiation of HMAs,\textsuperscript{30,31} type of HMAs, use of antibacterial prophylaxis, and treatment responses to HMAs. Responses to the HMAs were evaluated according to the International Working Group.\textsuperscript{32–34} Patients who responded to treatment were defined as achieving a complete response (CR) or partial response (PR) in AML and CR or PR or hematologic improvement in MDS.

\textbf{Statistical analysis}

Baseline characteristics were compared between the groups using the Mann–Whitney \textit{U} test or chi-squared test, as appropriate. Factors affecting the incidence of IFIs were assessed using univariate and multivariate logistic regression analyses with the following variables for identifying the overall condition of the patient: age, diagnosis of AML or MDS, ECOG PS, characteristics at the initiation of HMAs (ANC, CPS, and CKD stage), type of HMAs, use of antibacterial prophylaxis, and treatment responses to HMAs. The IBM Statistical Package for Social Sciences version 21.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. A \( p \) value < 0.05 was considered statistically significant.

\textbf{Results}

\textbf{Patient characteristics}

In total, 280 AML or MDS patients treated with HMAs were analyzed in this study (no-use group: \( n = 148 \); posaconazole group: \( n = 132 \)). In the case of MDS patients (total, 198 patients), the median ANC at diagnosis was 1096/\( \mu L \) with a range of 33 to 63,909/\( \mu L \) [no use: 969/\( \mu L \) (median), 91–29,856/\( \mu L \) (range); posaconazole: 1276/\( \mu L \), 33–63,909/\( \mu L \) and the median time to treatment from diagnosis was 0.50 months with a range of 0.03 to 80.67 months (no use: 0.47 months, 0.07–80.67 months; posaconazole: 0.59 months, 0.03–75.90 months). The baseline characteristics at HMA initiation of each group are summarized in Table 1. The posaconazole group showed a higher median age than the no-use group [no use: 70.5 years (median), 31.0–86.0 years (range); posaconazole: 74.0 years, 21.0–87.0 years; \( p = 0.009 \)]. The posaconazole group also showed a higher proportion of patients with AML diagnosis (no use: 30/148 patients, 20.3%; posaconazole: 52/132 patients, 39.4%; \( p = 0.001 \)), decreased liver function (defined as having CPS more than 7; no use: 12/148 patients, 8.1%; posaconazole: 27/132 patients, 20.5%; \( p = 0.003 \)), decreased kidney function (defined as having CKD stage 3, 4, or 5; no use: 46/148 patients, 31.1%; posaconazole: 75/132 patients, 56.8%; \( p < 0.001 \), and decitabine use (no use: 91/148 patients, 61.5%; posaconazole: 99/132 patients, 75.0%; \( p = 0.021 \)). In contrast, the proportion of antibacterial prophylaxis use was higher in the posaconazole group than in the no-use group (no use: 77/148 patients, 52.0%; posaconazole: 95/132 patients, 72.0%; \( p = 0.001 \)). However, there were no significant differences in the other characteristics between the groups, including sex, proportion of patients with poor prognostic risk, ECOG PS, proportion of neutropenia, and responses during treatment.

\textbf{IFIs}

The median number of HMA chemotherapy cycles was five cycles (range: 1–72 cycles) in the no-use group and four cycles (range: 1–28 cycles) in the posaconazole group. In total, 22 out of 280 patients were identified with probable or proven IFIs (overall incidence of IFIs: 7.9%) and the details of each IFI are summarized in Tables 2 and 3. The overall incidence of probable or proven IFIs was 11.5% in the no-use group (17/148 patients) and 3.8% in the posaconazole group (5/132 patients); of these, the incidence of invasive mold infections was 8.1% in the no-use group (12/148 patients) and 3.8% in the posaconazole group (5/132 patients). The patients with probable or proven IFIs showed a median age of 69.5 years (range: 21–82 years) and 27.3% of the patients had AML. The median values of the HMA chemotherapy cycle and ANC at the time of IFI diagnosis were 3 (range: 1–6 cycles) and 100/\( \mu L \) (range: 0–2700/\( \mu L \)), respectively. The changes in the ANCs of each patient at the time of diagnosis, the start of HMA treatment, the time of IFI diagnosis, and over the 14 days before IFI diagnosis are summarized in Supplemental Figure 1, as is febrile neutropenia. At the time of IFI diagnosis, the proportion of patients who did not respond to HMAs and the
Table 1. Baseline characteristics at the initiation of hypomethylating agents.

| Baseline characteristics | Antifungal prophylaxis | p value |
|--------------------------|------------------------|---------|
|                          | No use n = 148         |         |
|                          | Antifungal prophylaxis using posaconazole n = 132 |         |
| Median age, years [range] | 70.5 [31.0–86.0]       | 0.009   |
|                          | 74.0 [21.0–87.0]       |         |
| <70 years, n (%)         | 68 [45.9]              | 0.010   |
|                          | 40 [30.3]              |         |
| ⩾70 years, n (%)         | 80 [54.1]              |         |
|                          | 92 [81.1]              |         |
| Male:female ratio        | 1.85                   | 0.620   |
|                          | 1.59                   |         |
| Primary diagnosis, n (%) |                       | 0.001   |
| Acute myelogenous leukemia† | 30 [20.3]             | 0.287   |
| Favorable risk           | 2 [6.7]                |         |
|                          | 5 [9.6]                |         |
| Intermediate risk        | 19 [63.3]              |         |
|                          | 39 [75.0]              |         |
| Poor risk                | 9 [30.0]               |         |
|                          | 8 [15.4]               |         |
| Myelodysplastic syndrome‡ | 118 [79.7]             | 0.884   |
| Very low, low, and intermediate risk | 66 [55.9] |         |
|                          | 46 [57.5]              |         |
| More than high risk      | 52 [44.1]              |         |
|                          | 34 [42.5]              |         |
| ECOG PS, n (%)           |                       | 0.791   |
| 0–1                     | 141 [95.3]             |         |
| ≥2                      | 7 [4.7]                |         |
| Neutropenia [absolute neutrophil count <1000 cells/μL], n (%) | 76 [51.4] | 0.072 |
|                          | 53 [40.2]              |         |
| Child–Pugh score, n (%)  |                       | 0.003   |
| 5–6                     | 136 [91.9]             |         |
| ≥7                      | 12 [8.1]               |         |
| CKD stage, n (%)*        |                       | <0.001  |
| Stage 1 and 2: eGFR ⩾60 | 102 [68.9]             |         |
|                          | 57 [43.2]              |         |
| Stages 3 and 4: 15 ⩽ eGFR <60 | 43 [29.1]             |         |
|                          | 70 [53.0]              |         |
| Stage 5: eGFR <15        | 3 [2.0]                |         |
|                          | 5 [3.8]                |         |
| Type of hypomethylating agent, n (%) |               | 0.021  |
| Azacytidine              | 57 [38.5]              |         |
|                          | 33 [25.0]              |         |
| Decitabine               | 91 [61.5]              |         |
|                          | 99 [75.0]              |         |
| Antibacterial prophylaxis, n (%) |               | 0.001  |
| No use                   | 71 [48.0]              |         |
|                          | 37 [28.0]              |         |

(Continued)
incidence of IFI-related death were 72.7% and 50%, respectively. In the univariate analysis, the posaconazole group showed a significantly lower incidence of IFIs than the no-use group [no use versus posaconazole, odds ratio (OR): 3.296, 95% confidence interval (CI): 1.181–9.201, \(p=0.023\)]. In the multivariate analysis of IFI incidence, the use of posaconazole as antifungal prophylaxis led to a significant reduction of IFI incidence (no use versus posaconazole, OR: 3.921, 95% CI: 1.964–7.826, \(p<0.001\)). In addition, patients who had reduced liver function at HMA initiation, were treated with decitabine therapy, and did not respond to HMA chemotherapy were independently associated with a higher risk of IFIs (OR: 2.775, 95% CI: 1.161–6.632, \(p=0.022\); OR: 3.237, 95% CI: 1.633–6.418, \(p<0.001\); and OR: 7.227, 95% CI: 3.849–13.567, \(p<0.001\), respectively) (Table 4). Receiver operating characteristic (ROC) curve analysis was conducted to assess the predictability potential of the four variables for IFIs, and the resultant ROC curve is shown in Figure 1. The area under the curve (AUC) value for this ROC curve was 0.780. The ROC curve displayed a sensitivity of 0.80 and a specificity of 0.64 for predicting IFIs in AML or MDS patients treated with HMAs. Cross validation was performed to test the predictability potential of the four variables. The AUC value for the ROC curve of the cross-validation model was 0.703. The sensitivity and specificity for this validation model were 0.80 and 0.63, respectively.

Subgroup analysis for the incidence of IFIs according to the use of posaconazole as antifungal prophylaxis

To further investigate which subgroups would benefit from the use of posaconazole as antifungal prophylaxis, subgroup analysis of the following factors was performed: age, diagnosis, characteristics at HMA initiation (ECOG PS, ANC, CPS, and eGFR), type of HMA, use of antibacterial prophylaxis, and treatment responses to HMAs (Figure 2). In the subgroup analysis, the use of posaconazole significantly decreased the incidence of IFIs in the groups with 0–1 ECOG PS and in the groups with 5–6 CPS (OR: 0.230, 95% CI: 0.061–0.866, \(p=0.030\) and OR: 0.254, 95% CI: 0.064–1.001, \(p=0.050\), respectively). No other subgroups benefited from the use of posaconazole as antifungal prophylaxis.

In addition, we further analyzed whether there was medical history that could increase the risk of IFI in patients with AML and MDS. In the
| Case | Age (years) | Sex | WHO diagnosis | Antifungal prophylaxis | HMA cycle at IFI diagnosis | HMA cycle with febrile neutropenia | ANC at IFI diagnosis (μL) | Response to HMAS | Category of IFI per EORTC/MSG | Host factor | Clinical criteria | Mycological criteria | Treatment outcome of IFI |
|------|-------------|-----|---------------|-----------------------|--------------------------|-------------------------------|--------------------------|---------------------|-----------------------------|-------------|-----------------|-------------------|---------------------|
| 1    | 53          | Male| MDS           | No use                | 1                        | 1                             | 812                       | SD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | Resolved          |
| 2    | 52          | Female | MDS          | No use                | 2                        | –                             | 1771                      | HI                  | Proven – | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | IFI-related death |
| 3    | 56          | Male | MDS           | No use                | 2                        | 1, 2                          | Not detectable            | PD                  | Proven Recent history of neutropenia | Lower respiratory tract fungal disease | Candida tropicalis (blood culture) | IFI-related death |
| 4    | 80          | Female | AML          | No use                | 5                        | 1, 2, 3, 4                    | 19                        | CR                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | Resolved          |
| 5    | 76          | Female | AML           | No use                | 2                        | 1                             | 1800 [IC 92%]             | NA                  | Proven – | Lower respiratory tract fungal disease | Candida glabrata (blood culture) | IFI-related death |
| 6    | 81          | Male | AML           | No use                | 2                        | 1, 2                          | 875                       | PD                  | Proven Recent history of neutropenia | Candida parapsilosis (blood culture) | IFI-related death |
| 7    | 49          | Male | MDS           | No use                | 3                        | 1, 2, 3                        | 211                       | PD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | Resolved          |
| 8    | 81          | Male | AML           | No use                | 3                        | 1, 3                          | 864                       | PD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | β-D-glucan (+) | IFI-related death |
| 9    | 68          | Male | MDS           | No use                | 3                        | 1, 2, 3                        | 1190                      | PR                  | Proven – | Sinonasal infection, lower respiratory tract fungal disease | Aspergillus flavus (sputum culture, nasopharyngeal biopsy) | Resolved |
| 10   | 75          | Male | MDS           | No use                | 6                        | 1, 2                          | 2700 [IC 20%]             | PD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | β-D-glucan (+) | IFI-related death |
| 11   | 52          | Female | MDS         | No use                | 1                        | 1                             | 68                        | SD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | Resolved          |
| 12   | 63          | Male | MDS           | No use                | 4                        | 1, 2, 3, 4                    | 13                        | SD                  | Probable Recent history of neutropenia | Lower respiratory tract fungal disease | Aspergillosis Ag (+) | IFI-related dead  |

(Continued)
Febrile neutropenia was defined according to the National Comprehensive Cancer Network guidelines (prevention and treatment of cancer-related infections, version 2.2020). Microbiologic criteria for probable infection with Aspergillus species included a positive test for the aspergillus galactomannan antigen (≥0.5 on the galactomannan index) and β-D-glucan (≥80 pg/mL) in serum.

AML, acute myeloid leukemia; ANC, absolute neutrophil count; CR, complete remission; EORTC/MSG, European Organization for Research and Treatment of Cancer/Myelodysplastic Syndromes Group; HMA, hypomethylating agent; IC, immature cell; IFI, invasive fungal infection; MDS, myelodysplastic syndrome; NA, not applicable; PD, progressive disease; PR, partial remission; SD, stable disease; WHO, World Health Organization.

Table 2. (Continued)
Table 3. Patient characteristics at the time of IFI diagnosis.

| Characteristics                        | No use | Antifungal prophylaxis using posaconazole | Total |
|----------------------------------------|--------|------------------------------------------|-------|
|                                        | n=17   | n=5                                      | N=22  |
| Median age, years (range)              | 63.0 (41–82) | 78.0 [21–82] | 69.5 [21–82] |
| Primary diagnosis, n [%]               |        |                                          |       |
| Acute myelogenous leukemia†            | 4 (23.5) | 2 (40) | 6 (27.3) |
| Favorable risk                         | 0 [0] | 0 [0] | 0 [0] |
| Intermediate risk                      | 2 (50) | 2 (100) | 4 (66.7) |
| Poor risk                              | 2 (50) | 0 [0] | 2 (33.3) |
| Myelodysplastic syndrome‡              | 13 (76.5) | 3 (60) | 16 (72.7) |
| Very low, low, and intermediate risk   | 10 (76.9) | 3 (100) | 13 [81.2] |
| More than high risk                    | 3 (23.1) | 0 [0] | 3 (18.8) |
| HMA cycle at IFI diagnosis (range)     | 2 [1–6] | 3 [2–5] | 3 [1–6] |
| ANC at IFI diagnosis, /μL (range)      | 211 [0–2700] | 36 [20–350] | 100 [0–2700] |
| No response to HMAs, n [%]*            | 12 (70.6) | 4 (80.0) | 16 [72.7] |
| IFI-related death, n [%]               | 10 [59] | 1 [20] | 11 [50] |

†Cytogenetics-molecular risk stratification of acute myelogenous leukemia was classified according to the 2017 European LeukemiaNet criteria.
‡Prognosis risk groups of myelodysplastic syndrome were divided according to the revised international prognostic scoring system.
*The analysis was conducted except for the missing value of 9.1% (total 2/22 patients, no use: n=2, and posaconazole: n=0).
ANC, absolute neutrophil count; HMA, hypomethylating agent; IFI, invasive fungal infection.

Table 4. Univariate and multivariate analyses of the incidence of invasive fungal infections.

| Variables                                | Univariate analysis | Multivariate analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | OR (95% CI)         | p value               | OR (95% CI)         | p value               |
| No use versus posaconazole               | 3.296 [1.181–9.201] | 0.023                 | 4.483 [2.280–8.813] | <0.001               |
| Age ≥70 years versus <70 years           | 0.602 [0.252–1.442] | 0.255                 | –                     | –                     |
| Acute myeloid leukemia versus myelodysplastic syndrome | 0.933 [0.374–2.327] | 0.882                 | –                     | –                     |
| ECOG PS ≥2 versus ECOG PS 0–1†           | 0.717 [0.090–5.694] | 0.753                 | –                     | –                     |
| ANC <1000/μL versus ANC ≥1000/μL†         | 1.855 [0.803–4.286] | 0.148                 | –                     | –                     |
| Child–Pugh score ≥7 versus 5–6†          | 1.197 [0.388–3.696] | 0.754                 | 2.775 [1.161–6.632] | 0.022                 |
| 15 ≤ eGFR <60 versus eGFR ≥60‡*          | 1.006 [0.430–2.352] | 0.99                  | –                     | –                     |
| eGFR <15 versus eGFR ≥60‡*              | 1.480 [0.17–12.906] | 0.723                 | –                     | –                     |
| Decitabine versus azacitidine            | 1.556 [0.599–4.039] | 0.364                 | 3.237 [1.633–6.418] | <0.001               |
| Antibacterial prophylaxis versus no use† | 0.654 [0.287–1.492] | 0.313                 | –                     | –                     |
| Treatment response (−) versus response (+) | 6.562 [2.154–19.995] | 0.001                | 7.227 [3.849–13.567] | <0.001               |

†These characteristics were measured at the initiation of hypomethylating agents.
‡eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation.
ANC, absolute neutrophil count; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; eGFR, estimated glomerular filtration rate; OR, odds ratio.
univariate logistic regression analyses, there were no histories that raised the risk of IFI, including hypertension (yes: 108 versus no: 172, OR 0.725, 95% CI 0.286–1.841, p=0.499), diabetes (yes: 70 versus no: 210, OR 1.145, 95% CI 0.406–3.227, p=0.798), cardiovascular diseases (including angina, arrhythmia, valvular heart disease, and heart failure; yes: 17 versus no: 263, OR 0.720, 95% CI 0.091–5.701, p=0.756) and cerebral diseases (including cerebral infarction and Parkinson’s disease; yes: 10 versus no: 270, OR 1.317, 95% CI 0.159–10.904, p=0.798). Cases of pulmonary diseases, autoimmune diseases, preceding hematologic diseases, previous history of solid cancer diagnosis, and occupational exposure could not be analyzed because of small sample sizes or insufficient data.

Adverse events leading to the discontinuation of posaconazole
There were no reports of grade 3 or higher adverse events requiring the interruption or discontinuation of posaconazole treatment.

Discussion
In this study, the overall incidence of probable or proven IFIs in AML and MDS patients treated with HMAs as first-line chemotherapy was 7.9%: 11.5% in the no-use group and 3.8% in the posaconazole group. Among the IFIs, the overall incidence of invasive mold infection was 6.1%: 8.1% in the no-use group and 3.8% in the posaconazole group. Although the posaconazole group had a higher median age and proportion of patients with AML diagnosis and lower liver or kidney function at HMA initiation than the no-use group, the use of posaconazole as antifungal prophylaxis during HMA treatment significantly reduced the incidence of IFIs. In the subgroup analysis, this advantage of posaconazole appeared to be greater in patients with good ECOG PS or liver function at HMA initiation. Moreover, this study suggested other factors associated with a higher risk of IFIs, including reduced liver function at HMA initiation, the use of decitabine, and a poor response to HMAs.

Previous studies on the incidence of IFIs in patients treated with HMAs are summarized in Table 5.35–37 In these studies, the incidence of IFIs ranged from 3.3% to 12.5%, which is consistent with the incidence range obtained in the present study (overall incidence: 7.9%). As most previous studies did not provide information on the use of antifungal prophylaxis or used antifungal prophylaxis in less than 30% of patients, it is difficult to directly compare the efficacy of posaconazole as antifungal prophylaxis. However, considering that the median value of IFI incidence in the previous studies was 8.8% (range: 3.3–12.5%), the 3.8% IFI incidence in the posaconazole group in the present study was considered relatively lower than that in the previous studies. In addition, in the present study, the overall incidence of invasive mold infections in the no-use group was 8.1% (12/148 patients), which exceeds the 8% threshold of the incidence of invasive mold infections set by the European Conference on Infections for the recommendation of antifungal prophylaxis.17 Collectively, the results of the present study suggest that the use of antifungal prophylaxis in AML or MDS patients treated with HMAs is reasonable, and one of the options could be posaconazole.

In this study, the characteristics at the time of IFI diagnosis were further summarized to identify patients with a risk of IFIs (Table 3). First, the proportion of AML patients was 27.3% (no-use group: 23.5%, posaconazole group: 40%), suggesting that the risk of developing IFIs could be considered even in MDS patients treated with
Second, most cases of IFIs in the present study occurred during the early cycles of HMA treatment (median: 3 cycles; range: 1–6 cycles), consistent with previously published results (Table 5). Third, in most cases, ANC was less than 1000/μL at the time of IFI diagnosis. In half of the cases with ANC more than 1000/μL, immature cells were observed in peripheral blood. Neutropenia or immature cells could indicate that the underlying disease was not controlled at the time of IFI diagnosis. In addition, the response to HMA treatment was independently associated with a risk of IFIs in the present study (Table 4). Based on these results, during the early cycles of HMAs, especially until the confirmation of the improvement of cytopenia or response to treatment, the risk of IFIs may be high and the possibility of IFIs among causes of infections should be considered even in MDS patients treated with HMAs.

Posaconazole use as antifungal prophylaxis should be limited to well-accepted indications to avoid excessive cost, toxicity, and antimicrobial resistance.\(^{38}\) To find the patient groups that benefit more from posaconazole, we conducted a subgroup analysis. In the present study, posaconazole as antifungal prophylaxis significantly decreased
Table 5. Previous studies on the incidence of IFIs in patients treated with HMAs.

| Study            | Subjects                                      | No.  | Use of antifungal prophylaxis | Category of IFIs | Incidence of IFIs | HMA cycle at IFIs | High-risk patients of IFIs |
|------------------|-----------------------------------------------|------|------------------------------|------------------|-------------------|-------------------|---------------------------|
| Merkel et al.    | AML or high-risk MDS patients treated with AZA| 184  | UK; 10.9% of patients were prescribed prophylactic antibiotics | UK               | 6/184 patients (3.3%) | UK; infections were more common during the first two cycles of HMAs | UK; the risk of infection was higher in patients with poor cytogenetics, PLT < 20 × 10⁹/L and ANC < 0.5 × 10⁹/L |
| Falantes et al.  | AML or MDS patients treated with AZA          | 64   | No use                       | Six cases of invasive aspergillosis were probable; in the other two cases, no information was presented | 8/64 patients (12.5%) | UK; febrile episodes mainly occurred during the first three cycles of HMAs | Patients who received prior IC had more febrile episodes; the incidence of infection reached a plateau after 4–6 cycles of AZA among patients with <10% blasts and less severe cytopenia |
| Pomares et al.   | AML or MDS patients treated with AZA          | 121  | No use                       | One proven, one probable, and two possible | 4/121 patients (3.3%) | All IFI cases occurred within the second cycle of HMAs | Only two IFIs occurred in the context of severe neutropenia [ANC < 0.1 × 10⁹/L] |
| Trubiano et al.  | AML or MDS patients treated with AZA          | 68   | Antifungal prophylaxis in 30% of AZA cycles [268/884 cycles]; no information was given on the number of patients | All cases of IFIs were classified as the proven category | 6/68 patients (8.8%) | All IFI cases occurred within the second cycle of HMAs | UK; the risk of infection increased in patients with a very high risk of IPSS-R category |
| Kim et al.       | AML or MDS patients treated with AZA or DAC   | 203  | Fluconazole prophylaxis was administered to 11% of patients; patients receiving mold-active antifungal prophylaxis were excluded | Proven, probable, and possible IFIs were three, four, and 13 cases, respectively | 20/203 patients (9.6%) | The median number of cycles at the diagnosis of IFI was 3; only three cases occurred in the fifth cycle and beyond | The risk of IFIs increased in patients with therapy-related MDS or those who were neutropenic on the first day of the first cycle of HMA |
| The present study| AML or MDS patients treated with AZA or DAC   | 280  | No use: 148 patients; posaconazole: 132 patients | The proven and probable IFIs were five and 17 cases, respectively | 22/280 patients (7.9%) | The median number of cycles at the diagnosis of IFI was 3 [range: 1–6 cycles] | Posaconazole as antifungal prophylaxis led to a lower risk of IFIs; patients who had reduced liver function at HMA initiation, were treated with DAC therapy, and did not respond to HMA chemotherapy were independently associated with a higher risk of IFIs |

AML, acute myeloid leukemia; ANC, absolute neutrophil count; AZA, azacytidine; DAC, decitabine; HMA, hypomethylating agent; IFI, invasive fungal infection; IPSS-R, revised International Prognostic Scoring System; MDS, myelodysplastic syndrome; PLT, platelet; UK, unknown.
the incidence of IFIs in the groups with 0–1 ECOG PS and groups with 5–6 CPS at the initiation of HMAs. As posaconazole is an oral medication partly metabolized in the liver, it may lead to hepatotoxicity.39,40 Thus, posaconazole might not be beneficial for patients with poor compliance or reduced liver function. However, there was no definitive evidence supporting these hypotheses. Rather, considering that the risk of invasive infection is generally high when the performance status is poor41–43 and that delayed diagnosis and treatment are commonly caused by insufficient clinical symptoms in patients with reduced liver function,44,45 antifungal prophylaxis alone may not lower the risk of IFIs in patients with poor ECOG PS or reduced liver function at HMA initiation. The finding that reduced liver function at HMA initiation was an independent risk factor for IFIs in the present study may also support this hypothesis. However, the results of the present study alone are not enough to identify a subgroup that will obtain greater benefit from posaconazole; therefore, further studies are warranted.

The present study was conducted retrospectively with a small number of patients. Thus, the results of this study alone are insufficient to conclude whether the use of posaconazole as antifungal prophylaxis is recommended in AML or MDS patients treated with HMAs or to suggest a subgroup that will obtain greater benefit from posaconazole. In addition, as posaconazole was not compared with fluconazole or itraconazole, which can be generally used as a prophylactic antifungal agent, it is necessary to verify the cost-effectiveness of posaconazole compared with other antifungal agents. Nevertheless, this study provided meaningful insights into the incidence and characteristics of IFIs as well as the efficacy of posaconazole as antifungal prophylaxis in AML or MDS patients treated with HMAs.

**Conclusion**

In conclusion, in AML or MDS patients receiving treatment with HMAs, the risk of IFIs may be high during the early cycles of HMA treatment, especially when the underlying disease is not controlled. Posaconazole could be an option for antifungal prophylaxis in these patients, and further studies are needed to determine its appropriate indications.

---

**Author contributions**

BSK and KWK designed the study. KWK analyzed the registry, summarized the results, and wrote the manuscript. KWK, BHL, MJJ, ESY, DSK, SRL, HJS, CWC, YP, and BSK. performed patient management and maintained the registry. All authors approved the final version of the manuscript.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Data availability statement**

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Ethics approval**

The study was approved by the institutional review board, and all data were fully anonymized (IRB No. 2020AN0211, 2020GR0237, and 2020AS0137).

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the Korea Health Technology R&D Project from the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, South Korea (grant number: HI17C2072).

**Informed consent statement**

Informed consent was waived by the institutional review board because of the retrospective nature of the study and because the analysis used anonymous clinical data.

**ORCID iD**

Ka-Won Kang https://orcid.org/0000-0003-1462-0502

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Bhatt VR, Viola GM and Ferrajoli A. Invasive fungal infections in acute leukemia. *Ther Adv Hematol* 2011; 2: 231–247.
2. Hammond SP, Marty FM, Bryar JM, et al. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. *Am J Hematol* 2010; 85: 695–699.

3. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica* 2006; 91: 1068–1075.

4. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. *Ann Intern Med* 1993; 118: 495–503.

5. Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). *Clin Infect Dis* 2015; 61: 324–331.

6. Pomares H, Arnan M, Sanchez-Ortega I, et al. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? *Mycoses* 2016; 59: 516–519.

7. Kim GY, Burns J, Freyer CW, et al. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. *Am J Hematol* 2020; 95: 792–798.

8. Leone G and Pagano L. Infections in myelodysplastic syndrome in relation to stage and therapy. *Mediterr J Hematol Infect Dis* 2018; 10: e2018039.

9. Mele L, Ricci P, Nosari A, et al. Invasive fungal infection in patients with myelodysplastic syndrome: a report of twelve cases. *Leuk Lymphoma* 2002; 43: 1613–1617.

10. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. *J Infect* 1998; 37: 173–180.

11. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 2005; 41: 634–653.

12. Lin SJ, Schranz J and Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. *Clin Infect Dis* 2001; 32: 358–366.

13. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). *Clin Infect Dis* 1999; 28: 1071–1079.

14. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2016; 14: 882–913.

15. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. *J Clin Oncol* 2018; 36: 3043–3054.

16. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011; 52: e56–e93.

17. Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother* 2018; 73: 3221–3230.

18. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. *Leukemia* 2013; 27: 1803–1812.

19. Toma A, Fenaux P, Dreyfus F, et al. Infections in myelodysplastic syndromes. *Haematologica* 2012; 97: 1459–1470.

20. Girmenia C, Candoni A, Delia M, et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: expert panel consensus-based recommendations. *Blood Rev* 2019; 34: 16–25.

21. Groll AH and Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. *Expert Rev Anti Infect Ther* 2005; 3: 467–487.

22. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; 356: 348–359.

23. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391–2405.
24. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008; 46: 1813–1821.

25. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2017; 129: 424–447.

26. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. *Blood Cancer J* 2018; 8: 47.

27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; 5: 649–655.

28. Tsoris A and Marlar CA. Use of the Child Pugh score in liver disease. Treasure Island, FL: StatPearls Publishing LLC, 2020.

29. Levin A and Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. *Kidney Int* 2014; 85: 49–61.

30. Zatko T, Kolena B, Petrovicova I, et al. Use of selected prediction equations (CG, MDRD4, CKD-EPI) in improving glomerular filtration rate assessment in clinical practice in Slovakia. *Cent Eur J Public Health* 2014; 22: 34–41.

31. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150: 604–612.

32. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 2003; 21: 4642–4649.

33. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood* 2006; 108: 419–425.

34. Platzbecker U, Fenaux P, Ades L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. *Blood* 2019; 133: 1020–1030.

35. Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. *Am J Hematol* 2013; 88: 130–134.

36. Falantes JF, Calderon C, Marquez-Malaver FJ, et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. *Clin Lymphoma Myeloma Leuk* 2014; 14: 80–86.

37. Trubiano JA, Dickinson M, Thursky KA, et al. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. *Leuk Lymphoma* 2017; 58: 2379–2386.

38. Enzler MJ, Berbari E and Osmon DR. Antimicrobial prophylaxis in adults. *Mayo Clin Proc* 2011; 86: 686–701.

39. Chen L, Krekels EHJ, Verweij PE, et al. Pharmacokinetics and pharmacodynamics of posaconazole. *Drugs* 2020; 80: 671–695.

40. Posaconazole. *LiverTox: clinical and research information on drug-induced liver injury*. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012.

41. Netelenbos T, Massey E, de Wreede LC, et al. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. *Transfusion* 2019; 59: 160–168.

42. Huang C-T, Liu C-J, Ko P-S, et al. Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma. *BMC Infect Dis* 2013; 21: 4642–4649.

43. Dumontet C, Hulin C, Dimopoulos MA, et al. A predictive model for risk of early grade ≥3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. *Leukemia* 2018; 32: 1404–1413.

44. Hassan EA, Abd El-Rehim AS, Hassany SM, et al. Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion. *Int J Infect Dis* 2014; 23: 69–74.

45. Falcone M, Massetti AP, Russo A, et al. Invasive aspergillosis in patients with liver disease. *Med Mycol* 2011; 49: 406–413.